Sleep Disorders

Neurology News Network for the week ending April 15, 2023. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 14, 2023.

A derived Obstructive Sleep Apnea score of 2-3 and cumulative sleep symptoms were found to be associated with a significantly higher odds of acute stroke.

Here's some of what is coming soon to NeurologyLive® this week.

Incidence of narcolepsy increased 4.17- and 1.42-fold during and after the 2009 H1N1 pandemic when compared with baseline.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is multiple sclerosis (MS).

Neurology News Network for the week ending April 8, 2023. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 7, 2023.

Evidence from a nationwide healthcare system data in South Korea showed that narcolepsy is closely related to systemic autoimmune diseases, particularly those related to HLA genes.

Pitolisant will be assessed in 200 patients with idiopathic hypersomnia, using change in excessive daytime sleepiness as the primary end point.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Parkinson disease (PD).

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 31, 2023.

Pitolisant, marketed as Wakix, recently received approval from the European Medicines Agency for pediatric narcolepsy with or without cataplexy.

Over a 6-month open-label extension period, mazindol ER was found to be safe, with patients demonstrating significant decreases in number of weekly cataplexy episodes and improvements in daytime sleepiness.

Pitolisant, a selective histamine H3 receptor inverse agonist, reduced the frequency of cataplexy in pediatric patients with narcolepsy.

In a phase 3 study, extended-release sodium oxybate demonstrated statistically significant and clinically meaningful results in excessive daytime sleepiness, clinician’s assessment of patient’s functioning, and reduction in cataplexy attacks.

An evaluation on the long-term treatment profile of sodium oxybate on pediatrics with narcolepsy revealed a safety profile similar to previous adult studies and identified no unexpected safety concerns.

The assistant professor of pediatrics at Harvard Medical School provided perspective on the care needs of adolescents and young adults with narcolepsy, and the importance of early detection of lingering issues. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network for the week ending March 25, 2023. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 24, 2023.

Results of solriamfetol were similar when outcomes were examined in subgroups of concomitant antidepressant use, regardless of depression history, indicating that antidepressants did not affect the efficacy of the drug.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Eric Zhou. [LISTEN TIME: 14 minutes]

Here's some of what is coming soon to NeurologyLive® this week.